Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME).

Date publication

juillet 2021

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr COUDERT Bruno , Pr PETIT Thierry

Tous les auteurs :
Dano D, Lardy-Cleaud A, Monneur A, Quenel-Tueux N, Levy C, Mouret-Reynier MA, Coudert B, Mailliez A, Ferrero JM, Guiu S, Campone M, de La Motte Rouge T, Petit T, Pistilli B, Dalenc F, Simon G, Lerebours F, Chabaud S, Bertucci F, Gonçalves A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34303929

Résumé

Primary inflammatory breast cancer (IBC) is a rare and aggressive entity whose prognosis has been improved by multimodal therapy. However, 5-year overall survival (OS) remains poor. Given its low incidence, the prognosis of IBC at metastatic stage is poorly described.

Mots clés

inflammatory breast cancer, metastatic breast cancer, multimodal therapy, prognostic factors, real-life study

Référence

ESMO Open. 2021 Jul 22;6(4):100220